Webinars & Videos

Radionuclide Drug Conjugates (RDCs) have shown great potential in early-stage tumor imaging and radioactive nuclide therapy. Read this WuXi TIDES case study to learn how the seamless transition from discovery to process development and manufacturing, across both small molecules and peptides, accelerated development of a challenging RDC candidate and IND submission. Milligram-scale discovery synthesis was completed in 1 month, and kilogram-scale manufacturing in just 3 months!

Peptide-oligonucleotide conjugates are made up of peptide and oligonucleotide components. These cutting-edge molecules have many applications in biomedicine. Dive into the video to learn more.

In this article, we will look specifically at the development challenge faced when moving a peptide-drug conjugate (PDC) from pre-clinical (gram-scale) to phase I (kg-scale). New modality conjugations with HPAPIs and peptides – particularly for oncology targets – are now an increasingly large part of the discovery pipeline.

This video demonstrate WuXi TIDES unique peptide CRDMO platform, state-of-the-art facility R&D labs, API & drug product manufacturing plants.

WuXi TIDES Oligonucleotide, Peptide & Complex Conjugates Business Introduction

PDCs have gained extensive attention as they are being proven successful in treating cancers recently with their superior target-specific delivery. Here we discuss how we overcome challenges and demonstrate opportunities through case studies.